{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T02:10:09Z","timestamp":1742004609781,"version":"3.38.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00520-025-09219-w","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T01:04:46Z","timestamp":1739408686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3045-1710","authenticated-orcid":false,"given":"Zhenzhen","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-0131","authenticated-orcid":false,"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"Suppl 1","key":"9219_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ijlh.13954","volume":"44","author":"GL Thompson","year":"2022","unstructured":"Thompson GL, Kavanagh D (2022) Diagnosis and treatment of thrombotic microangiopathy. Int J Lab Hematol 44(Suppl 1):101\u2013113","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"9219_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.34067\/KID.0000000000000061","volume":"4","author":"AM Aklilu","year":"2023","unstructured":"Aklilu AM, Shirali AC (2023) Chemotherapy-associated thrombotic microangiopathy. Kidney360 4(3):409\u2013422","journal-title":"Kidney360"},{"issue":"7","key":"9219_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371(7):654\u2013666","journal-title":"N Engl J Med"},{"issue":"5","key":"9219_CR4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajh.23960","volume":"90","author":"JA Reese","year":"2015","unstructured":"Reese JA, Bougie DW, Curtis BR, Terrell DR, Vesely SK, Aster RH, George JN (2015) Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin. Am J Hematol 90(5):406\u2013410","journal-title":"Am J Hematol"},{"key":"9219_CR5","doi-asserted-by":"publisher","first-page":"566678","DOI":"10.3389\/fmed.2021.566678","volume":"8","author":"N Henry","year":"2021","unstructured":"Henry N, Mellaza C, Fage N, Beloncle F, Genevieve F, Legendre G, Orvain C, Garnier AS, Cousin M, Besson V, Subra JF, Duveau A, Augusto JF, Brilland B (2021) Retrospective and systematic analysis of causes and outcomes of thrombotic microangiopathies in routine clinical practice: an 11-year study. Front Med (Lausanne) 8:566678","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"9219_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN (2015) Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125(4):616\u2013618","journal-title":"Blood"},{"issue":"9","key":"9219_CR7","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1002\/ajh.25208","volume":"93","author":"R Saleem","year":"2018","unstructured":"Saleem R, Reese JA, George JN (2018) Drug-induced thrombotic microangiopathy: an updated systematic review, 2014\u20132018. Am J Hematol 93(9):E241\u2013E243","journal-title":"Am J Hematol"},{"issue":"2","key":"9219_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12185-008-0140-1","volume":"88","author":"R Morita","year":"2008","unstructured":"Morita R, Hashino S, Shirai S, Fujita N, Onozawa M, Kahata K, Kondo T, Imamura M, Asaka M (2008) Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 88(2):248\u2013250","journal-title":"Int J Hematol"},{"issue":"4","key":"9219_CR9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1445-5994.2011.02458.x","volume":"41","author":"H Moore","year":"2011","unstructured":"Moore H, Romeril K (2011) Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Intern Med J 41(4):348\u2013350","journal-title":"Intern Med J"},{"issue":"2","key":"9219_CR10","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.4081\/hr.2012.e13","volume":"4","author":"U Salmenniemi","year":"2012","unstructured":"Salmenniemi U, Remes K (2012) Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 4(2):e13","journal-title":"Hematol Rep"},{"key":"9219_CR11","doi-asserted-by":"publisher","first-page":"bcr2012006461","DOI":"10.1136\/bcr-2012-006461","volume":"2012","author":"N Mehta","year":"2012","unstructured":"Mehta N, Saxena A, Niesvizky R (2012) Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Rep 2012:bcr2012006461","journal-title":"BMJ Case Rep"},{"issue":"7","key":"9219_CR12","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.3109\/10428194.2014.977887","volume":"56","author":"KL Chan","year":"2015","unstructured":"Chan KL, Filshie R, Nandurkar H, Quach H (2015) Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leuk Lymphoma 56(7):2185\u20132186","journal-title":"Leuk Lymphoma"},{"key":"9219_CR13","first-page":"6020691","volume":"2016","author":"J Van Keer","year":"2016","unstructured":"Van Keer J, Delforge M, Dierickx D, Peerlinck K, Lerut E, Sprangers B (2016) Renal thrombotic microangiopathy associated with the use of bortezomib in a patient with multiple myeloma. Case Rep Hematol 2016:6020691","journal-title":"Case Rep Hematol"},{"issue":"39","key":"9219_CR14","doi-asserted-by":"publisher","first-page":"e17148","DOI":"10.1097\/MD.0000000000017148","volume":"98","author":"CA Cassol","year":"2019","unstructured":"Cassol CA, Williams MPA, Caza TN, Rodriguez S (2019) Renal and pulmonary thrombotic microangiopathy triggered by proteasome-inhibitor therapy in patient with smoldering myeloma: a renal biopsy and autopsy case report. Medicine (Baltimore) 98(39):e17148","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"9219_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s13730-021-00603-z","volume":"10","author":"S Mizuno","year":"2021","unstructured":"Mizuno S, Kitayama C, Sanada S, Sato T (2021) Bortezomib-induced glomerular microangiopathy complicated with monoclonal immunoglobulin deposition disease. CEN Case Rep 10(4):537\u2013542","journal-title":"CEN Case Rep"},{"issue":"2","key":"9219_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/hematolrep14020018","volume":"14","author":"RC Sterner","year":"2022","unstructured":"Sterner RC, Rose WN (2022) Unique presentation of bortezomib-associated thrombotic microangiopathy responsive to therapeutic plasma exchange and eculizumab therapy. Hematol Rep 14(2):119\u2013125","journal-title":"Hematol Rep"},{"issue":"4","key":"9219_CR17","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1002\/ajh.24662","volume":"92","author":"JC Yui","year":"2017","unstructured":"Yui JC, Dispenzieri A, Leung N (2017) Ixazomib-induced thrombotic microangiopathy. Am J Hematol 92(4):E53\u2013E55","journal-title":"Am J Hematol"},{"key":"9219_CR18","first-page":"7063145","volume":"2018","author":"SA Atallah-Yunes","year":"2018","unstructured":"Atallah-Yunes SA, Soe MH (2018) Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib. Case Rep Hematol 2018:7063145","journal-title":"Case Rep Hematol"},{"issue":"3","key":"9219_CR19","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1097\/HS9.0000000000000192","volume":"3","author":"V Higuero Saavedra","year":"2019","unstructured":"Higuero Saavedra V, Gonzalez-Calle V, Sobejano E, Sebastia J, Cabrero M, Bastida JM, Puig N, Ocio EM, Mateos MV (2019) Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma. Hemasphere 3(3):e192","journal-title":"Hemasphere"},{"key":"9219_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2369-15-156","volume":"15","author":"L Hobeika","year":"2014","unstructured":"Hobeika L, Self SE, Velez JC (2014) Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 15:156","journal-title":"BMC Nephrol"},{"issue":"5","key":"9219_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/jca.21371","volume":"30","author":"MR Sullivan","year":"2015","unstructured":"Sullivan MR, Danilov AV, Lansigan F, Dunbar NM (2015) Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher 30(5):308\u2013310","journal-title":"J Clin Apher"},{"issue":"5","key":"9219_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ckj\/sfv059","volume":"8","author":"A Lodhi","year":"2015","unstructured":"Lodhi A, Kumar A, Saqlain MU, Suneja M (2015) Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J 8(5):632\u2013636","journal-title":"Clin Kidney J"},{"issue":"4","key":"9219_CR23","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.clml.2020.01.016","volume":"20","author":"D Bhutani","year":"2020","unstructured":"Bhutani D, Assal A, Mapara MY, Prinzing S, Lentzsch S (2020) Case report: carfilzomib-induced thrombotic microangiopathy with complement activation treated successfully with eculizumab. Clin Lymphoma Myeloma Leuk 20(4):e155\u2013e157","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"9219_CR24","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ccr3.1214","volume":"5","author":"R Gosain","year":"2017","unstructured":"Gosain R, Gill A, Fuqua J, Volz LH, KessansKnable MR, Bycroft R, Seger S, Gosain R, Rios JA, Chao JH (2017) Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep 5(12):1926\u20131930","journal-title":"Clin Case Rep"},{"issue":"4","key":"9219_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.nephro.2020.03.006","volume":"16","author":"C Casiez","year":"2020","unstructured":"Casiez C, Pica GM, Bally S (2020) Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab. Nephrol Ther 16(4):221\u2013224","journal-title":"Nephrol Ther"},{"issue":"2","key":"9219_CR26","doi-asserted-by":"publisher","first-page":"e239091","DOI":"10.1136\/bcr-2020-239091","volume":"14","author":"A Darwin","year":"2021","unstructured":"Darwin A, Malpica L, Dhanoa J, Hashmi H (2021) Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Rep 14(2):e239091","journal-title":"BMJ Case Rep"},{"issue":"12","key":"9219_CR27","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.ekir.2022.09.006","volume":"7","author":"C Philipponnet","year":"2022","unstructured":"Philipponnet C, Aniort J, Atenza A, Heng AE, Souweine B (2022) Carfilzomib induced microangiopathy due to accumulation with paxlovid. Kidney Int Rep 7(12):2746\u20132749","journal-title":"Kidney Int Rep"},{"issue":"6","key":"9219_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.14740\/jmc3932","volume":"13","author":"O Eigbire-Molen","year":"2022","unstructured":"Eigbire-Molen O, Hermelin D, Blackall D (2022) Carfilzomib-induced thrombotic microangiopathy: focus on pathogenesis. J Med Cases 13(6):274\u2013280","journal-title":"J Med Cases"},{"issue":"3","key":"9219_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s13730-021-00681-z","volume":"11","author":"CD Hamad","year":"2022","unstructured":"Hamad CD, Hoelscher ZC, Tchakarov A, Kala J (2022) Influenza-induced thrombotic microangiopathy in a patient with cancer on proteasome inhibitor: a diagnostic dilemma. CEN Case Rep 11(3):321\u2013327","journal-title":"CEN Case Rep"},{"issue":"3","key":"9219_CR30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/10781552211067433","volume":"28","author":"V Scheggi","year":"2022","unstructured":"Scheggi V, Merilli I, Cesaroni E, Alterini B (2022) Carfilzomib-induced thrombotic microangiopathy. A case report. J Oncol Pharm Pract 28(3):754\u2013758","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"9219_CR31","first-page":"255","volume":"64","author":"S Matsumoto","year":"2023","unstructured":"Matsumoto S, Takahashi H, Hamada T, Miura K, Nakagwa M, Kurihara K, Endo T, Koike T, Iizuka K, Iriyama N, Nakayama T, Hatta Y, Nakamura H (2023) Thrombotic microangiopathy with gastrointestinal hemorrhage during carfilzomib therapy for multiple myeloma. Rinsho Ketsueki 64(4):255\u2013259","journal-title":"Rinsho Ketsueki"},{"issue":"4","key":"9219_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.hemonc.2020.07.001","volume":"16","author":"N Jindal","year":"2023","unstructured":"Jindal N, Jandial A, Jain A, Lad D, Prakash G, Khadwal A, Nada R, Sethi J, Ahluwalia J, Malhotra P (2023) Carfilzomib-induced thrombotic microangiopathy: a case based review. Hematol Oncol Stem Cell Ther 16(4):426\u2013431","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"9219_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12882-023-03228-9","volume":"24","author":"L Catanese","year":"2023","unstructured":"Catanese L, Link K, Rupprecht H (2023) Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition. BMC Nephrol 24(1):179","journal-title":"BMC Nephrol"},{"issue":"7","key":"9219_CR34","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1038\/bcj.2016.62","volume":"6","author":"Y Chen","year":"2016","unstructured":"Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, Phipps C, Lee YS, Grigoropoulos NF, Lao Z, Surendran S, Teh EM, Goh YT, Chng WJ, Gopalakrishnan SK (2016) Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer J 6(7):e450","journal-title":"Blood Cancer J"},{"issue":"3","key":"9219_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.transci.2016.03.002","volume":"54","author":"I Qaqish","year":"2016","unstructured":"Qaqish I, Schlam IM, Chakkera HA, Fonseca R, Adamski J (2016) Carfilzomib: a cause of drug associated thrombotic microangiopathy. Transfus Apher Sci 54(3):401\u2013404","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"9219_CR36","doi-asserted-by":"publisher","first-page":"E348","DOI":"10.1002\/ajh.24447","volume":"91","author":"JC Yui","year":"2016","unstructured":"Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D\u2019Agati VD, Kastritis E, Dimopoulos MA, Vij R, Bansal D, Dingli D, Nasr SH, Leung N (2016) Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol 91(9):E348\u2013E352","journal-title":"Am J Hematol"},{"issue":"11","key":"9219_CR37","doi-asserted-by":"publisher","first-page":"e791","DOI":"10.1016\/j.clml.2020.04.014","volume":"20","author":"BE Monteith","year":"2020","unstructured":"Monteith BE, Venner CP, Reece DE, Kew AK, Lalancette M, Garland JS, Shepherd LE, Pater JL, Hay AE (2020) Drug-induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: a case series and review of the literature. Clin Lymphoma Myeloma Leuk 20(11):e791\u2013e800","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"9219_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bjh.16796","volume":"193","author":"M Blasco","year":"2021","unstructured":"Blasco M, Martinez-Roca A, Rodriguez-Lobato LG, Garcia-Herrera A, Rosinol L, Castro P, Fernandez S, Quintana LF, Cibeira MT, Blade J, Fernandez de Larrea C, Tovar N, Jimenez R, Poch E, Guillen E, Campistol JM, Carreras E, Diaz-Ricart M, Palomo M (2021) Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol 193(1):181\u2013187","journal-title":"Br J Haematol"},{"issue":"1","key":"9219_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12882-020-02226-5","volume":"22","author":"M Rassner","year":"2021","unstructured":"Rassner M, Baur R, Wasch R, Schiffer M, Schneider J, Mackensen A, Engelhardt M (2021) Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrol 22(1):32","journal-title":"BMC Nephrol"},{"issue":"Suppl 3","key":"9219_CR40","first-page":"S56","volume":"39","author":"NJ Myall","year":"2022","unstructured":"Myall NJ, Wang SX, Hall ET, Witteles WH, Leung L, Dunn TJ, Hong WJ (2022) Simultaneous cases of carfilzomib-induced thrombotic microangiopathy in 2 patients with multiple myeloma. Fed Pract 39(Suppl 3):S56\u2013S62","journal-title":"Fed Pract"},{"issue":"5","key":"9219_CR41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1080\/10428194.2022.2057485","volume":"63","author":"T Terao","year":"2022","unstructured":"Terao T, Tsushima T, Miura D, Ikeda D, Fukumoto A, Kuzume A, Tabata R, Narita K, Takeuchi M, Matsue K (2022) Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: a report of five patients and literature review. Leuk Lymphoma 63(5):1102\u20131110","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"9219_CR42","doi-asserted-by":"publisher","first-page":"E369","DOI":"10.1002\/ajh.27101","volume":"98","author":"N Klomjit","year":"2023","unstructured":"Klomjit N, Evans R, Le TK, Wells SL, Ortega J, Green-Lingren O, Mazepa M, Sise ME, Jhaveri KD, Gupta S (2023) Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: analysis from a large pharmacovigilance database. Am J Hematol 98(12):E369\u2013E372","journal-title":"Am J Hematol"},{"key":"9219_CR43","first-page":"1","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP et al (2023) Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review. Cardio Oncol 5:1\u201321","journal-title":"Cardio Oncol"},{"key":"9219_CR44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.yjmcc.2022.10.002","volume":"173","author":"C Tu","year":"2022","unstructured":"Tu C, Liu Y, Williams DR, Wu JC (2022) A transcriptomic atlas of drug-induced endothelial dysfunction in human endothelial cells. J Mol Cell Cardiol 173:115\u2013117","journal-title":"J Mol Cell Cardiol"},{"issue":"Suppl 1","key":"9219_CR45","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1182\/blood-2018-99-117824","volume":"132","author":"C Venner","year":"2018","unstructured":"Venner C, Leblanc R, Sandhu I et al (2018) A single-arm phase II study of high-dose weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed multiple myeloma after 1\u20133 prior therapies. Blood 132(Suppl 1):1984","journal-title":"Blood"},{"key":"9219_CR46","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/j.clml.2019.09.449","volume":"19","author":"B Monteith","year":"2019","unstructured":"Monteith B, Venner C, Reece D et al (2019) Unusual carfilzomib toxicity: three cases of drug-induced thrombotic microangiopathy (TMA) after treatment with high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wCCD). Clin Lym- phoma Myeloma Leuk 19:e272\u2013e273","journal-title":"Clin Lym- phoma Myeloma Leuk"},{"issue":"7","key":"9219_CR47","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK (2018) Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 19(7):953\u2013964","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"9219_CR48","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2017.35.15_suppl.8003","volume":"35","author":"FM Gay","year":"2017","unstructured":"Gay FM, Rota Scalabrini D, Belotti A et al (2017) Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). J Clin Oncol 35(15 Suppl):8003","journal-title":"J Clin Oncol"},{"issue":"8","key":"9219_CR49","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1158\/1535-7163.MCT-12-1010","volume":"12","author":"RJ Thapa","year":"2013","unstructured":"Thapa RJ, Chen P, Cheung M, Nogusa S, Pei J, Peri S, Testa JR, Balachandran S (2013) NF-kappaB inhibition by bortezomib permits IFN-gamma-activated RIP1 kinase-dependent necrosis in renal cell carcinoma. Mol Cancer Ther 12(8):1568\u20131578","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"9219_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10456-010-9189-6","volume":"13","author":"S Greenberger","year":"2010","unstructured":"Greenberger S, Adini I, Boscolo E, Mulliken JB, Bischoff J (2010) Targeting NF-kappaB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 13(4):327\u2013335","journal-title":"Angiogenesis"},{"issue":"8","key":"9219_CR51","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1681\/ASN.2018020184","volume":"29","author":"S Timmermans","year":"2018","unstructured":"Timmermans S, Abdul-Hamid MA, Potjewijd J, Theunissen R, Damoiseaux J, Reutelingsperger CP, van Paassen P, Limburg Renal R (2018) C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension. J Am Soc Nephrol 29(8):2234\u20132243","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"9219_CR52","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","volume":"2","author":"AJ Portuguese","year":"2018","unstructured":"Portuguese AJ, Lipe B (2018) Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. Blood Adv 2(23):3443\u20133446","journal-title":"Blood Adv"},{"key":"9219_CR53","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 13:300\u2013317","journal-title":"Clin J Am Soc Nephrol"},{"key":"9219_CR54","doi-asserted-by":"publisher","first-page":"101081","DOI":"10.1016\/j.tranon.2021.101081","volume":"14","author":"P Val\u00e9rio","year":"2021","unstructured":"Val\u00e9rio P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM (2021) Thrombotic microangiopathy in oncology - a review. Transl Oncol 14:101081","journal-title":"Transl Oncol"},{"issue":"1","key":"9219_CR55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-024-01182-9","volume":"14","author":"C Chen","year":"2024","unstructured":"Chen C, Li YW, Shi PF, Qian SX (2024) Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review. Blood Cancer J 14(1):196","journal-title":"Blood Cancer J"},{"key":"9219_CR56","doi-asserted-by":"publisher","first-page":"175628642312166","DOI":"10.1177\/17562864231216634","volume":"16","author":"C Wang","year":"2023","unstructured":"Wang C, Fang W, Sun W, Zhao S, Peng L (2023) Clinical characteristics, treatments, and outcomes of interferon-beta-induced thrombotic microangiopathy: a literature-based retrospective analysis. Ther Adv Neurol Disord 16:17562864231216634","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"9219_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ (2019) Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher 34(3):171\u2013354","journal-title":"J Clin Apher"},{"issue":"2","key":"9219_CR58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1537-2995.2004.00700.x","volume":"44","author":"JN George","year":"2004","unstructured":"George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB (2004) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 44(2):294\u2013304","journal-title":"Transfusion"},{"key":"9219_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","volume":"224","author":"A Zafar","year":"2023","unstructured":"Zafar A, Lim MY, Abou-Ismail MY (2023) Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature. Thromb Res 224:73\u201379","journal-title":"Thromb Res"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09219-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09219-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:36:09Z","timestamp":1742002569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09219-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9219"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09219-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"184"}}